Actinium Pharma enters research collaboration with Memorial Sloan Kettering

Actinium Pharmaceuticals (ATNM) has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to expand Actimab-A’s mutation agnostic mechanism of action. The collaboration has two specific objectives. The first objective is to study Actimab-A in combination with targeted therapies including FLT3 and menin inhibitors to define transcriptional profiles in AML cells following treatment with these combinations. The second objective is to assess the activity of Actimab-A-based combinations on primary AML patient-derived ex vivo samples from patients with and without prior Venetoclax + hypomethylating agent treatment. Actimab-A has demonstrated a mutation agnostic profile with positive clinical results in high-risk relapsed and refractory AML patients including those with a TP53 gene mutation, prior Venetoclax treatment and prior bone marrow transplant. Additionally, Actimab-A has demonstrated mechanistic synergy with improved antileukemic activity and /or tumor control with FLT3 inhibitors, menin inhibitors for NPM1 mutant and KMT2A rearrangement and IDH1&2 inhibitors in preclinical studies.